Key result
Slowing cIMT progression cuts CVD events ~9% per 10 μm/year reduction.
Why the study?
The study was conducted to quantify the association between the effects of interventions on carotid intima-media thickness progression and their effects on cardiovascular disease risk.
Does therapeutic reduction of carotid intima-media thickness (cIMT) progression reduce the risk of combined cardiovascular disease events in patients enrolled in randomized controlled trials?
Meta-Analysis (n=100,667)
Yes
Does therapeutic reduction of carotid intima-media thickness (cIMT) progression reduce the risk of combined cardiovascular disease events in patients enrolled in randomized controlled trials?
This large-scale Bayesian meta-regression of 119 RCTs validates carotid intima-media thickness (cIMT) progression as a surrogate marker for cardiovascular disease risk in clinical trials.
Answers are grounded in this paper and cite their sources.
Supports cIMT progression as valid surrogate for CVD events; confirms utility across 119 RCTs for trial design.
BACKGROUND: To quantify the association between effects of interventions on carotid intima-media thickness (cIMT) progression and their effects on cardiovascular disease (CVD) risk. METHODS: We systematically collated data from randomized, controlled trials. cIMT was assessed as the mean value at the common-carotid-artery; if unavailable, the maximum value at the common-carotid-artery or other cIMT measures were used. The primary outcome was a combined CVD end point defined as myocardial infarction, stroke, revascularization procedures, or fatal CVD. We estimated intervention effects on cIMT progression and incident CVD for each trial, before relating the 2 using a Bayesian meta-regression approach. RESULTS: We analyzed data of 119 randomized, controlled trials involving 100 667 patients (mean age 62 years, 42% female). Over an average follow-up of 3.7 years, 12 038 patients developed the combined CVD end point. Across all interventions, each 10 μm/y reduction of cIMT progression resulted in a relative risk for CVD of 0.91 (95% Credible Interval, 0.87-0.94), with an additional relative risk for CVD of 0.92 (0.87-0.97) being achieved independent of cIMT progression. Taken together, we estimated that interventions reducing cIMT progression by 10, 20, 30, or 40 μm/y would yield relative risks of 0.84 (0.75-0.93), 0.76 (0.67-0.85), 0.69 (0.59-0.79), or 0.63 (0.52-0.74), respectively. Results were similar when grouping trials by type of intervention, time of conduct, time to ultrasound follow-up, availability of individual-participant data, primary versus secondary prevention trials, type of cIMT measurement, and proportion of female patients. CONCLUSIONS: The extent of intervention effects on cIMT progression predicted the degree of CVD risk reduction. This provides a missing link supporting the usefulness of cIMT progression as a surrogate marker for CVD risk in clinical trials.
No takes yet. Share an insight, caveat, or question.
Willeit et al. (2020) conducted a meta-analysis in Cardiovascular disease risk and atherosclerosis (n=100,667). Therapeutic interventions reducing carotid intima-media thickness (cIMT) progression (antidiabetic, antihypertensive, dietary/vitamin, lipid-lowering, and other interventions) vs. Control or reference arm (arm anticipated to have the least effect or placebo) was evaluated on Combined cardiovascular disease (CVD) endpoint defined as myocardial infarction, stroke, revascularization procedures, or fatal CVD (RR 0.91 per 10 μm/y reduction in cIMT progression, 95% CI 0.87-0.94). Therapeutic interventions yielded a relative risk for combined CVD events of 0.91 for each 10 μm/year reduction in carotid intima-media thickness progression.
Synapse has enriched 10 related papers. Consider them for comparative context: